FDA 483 - Torrent Pharmaceuticals Limited - April 16, 2019

Torrent Pharmaceuticals Limited received a Form 483 citing significant deficiencies in quality control and manufacturing processes. Observations included failures in thoroughly investigating out-of-specification results, lack of adequate written procedures for process controls, and deficient routine calibration and qualification of manufacturing equipment. These issues indicate a systemic breakdown in ensuring product quality and compliance.